secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2023-12-27T23:59:59+00:00
Accession:  0001193125-23-304012
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma ups revolving credit facility to $1.8B, extends majority to Dec 2028
--------------------------------------------------------------------------------

- Borrowing capacity increased from $1.5B to $1.8B via Amendment No. 3.
- $1.69B of commitments extended to December 22, 2028; $110M remains at Oct 31, 2027.
- Facility remains unsecured; interest based on SOFR/base rate plus applicable margin.
- Covenants include max leverage ratio of 4.00x (4.50x post material acquisition) and min coverage of 2.50x.
- Proceeds for general corporate purposes; amendment effective December 22, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312523304012/0001193125-23-304012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312523304012/d656258d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-304012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer